Repository logo
Communities & Collections
Research Outputs
Fundings & Projects
People
Statistics
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. KMITL
  3. Publication
  4. Total Knee Arthroplasty versus Mesenchymal Stem Cell Therapy for Moderate Knee Osteoarthritis: An Umbrella Analysis of Clinical Outcomes, Quality of Life, and Safety
Loading...
Thumbnail Image

Total Knee Arthroplasty versus Mesenchymal Stem Cell Therapy for Moderate Knee Osteoarthritis: An Umbrella Analysis of Clinical Outcomes, Quality of Life, and Safety

Author(s)
Angthong, Chayanin
Vichayabhai, Tyler
Tatiya-Apitham, Phurin
Angthong, Wirana
Date Issued
March 31, 2026
Type
Article
DOI
10.5604/01.3001.0055.7770
Abstract

Background. Moderate knee osteoarthritis (Kellgren-Lawrence [KL] Grade 2-3) represents a critical therapeutic crossroads where patients must choose between regenerative strategies and surgical replacement. This umbrella analysis synthesizes current evidence regarding the clinical efficacy, quality of life, and safety profiles of mesenchymal stem cell (MSC) therapy relative to total knee arthroplasty (TKA).
Material and methods. Following PRISMA 2020 guidelines, we systematically searched seven databases (2016-2026). Screening of 1,211 records identified 242 unique papers for full-text assessment. Eligible studies included systematic reviews, meta-analyses, and large prospective cohorts (>50 participants) evaluating intra-articular MSCs or TKA in KL Grade 2-3 populations with ≥12-month follow-up.
Results. Our analysis reveals a profound evidence gap: zero studies directly compared MSC therapy to TKA in this population. Data from 30 high-quality studies demonstrate that MSC therapy significantly outperforms placebo and conservative management, yielding VAS pain reductions of 20-40 points and WOMAC functional improvements of 15-35 points at 12-24 months. Adipose-derived MSCs showed superior analgesia, while umbilical cord-derived MSCs optimized functional recovery. MSC therapy significantly reduced the hazard of TKA conversion (HR 0.52, p<0.001). At 36-60 months, conversion rates were 12.4% for MSCs versus 22.7% for control groups. Safety profiles remained favorable with serious adverse event rates <5%. 
Conclusions. 1. While MSC therapy is a demonstrably effective bridge for delaying TKA in selected KL Grade 2-3 patients, its comparative effectiveness and long-term durability relative to arthroplasty remain uncharacterized. 2. High-quality randomized controlled trials directly benchmarking MSCs against TKA are urgently required to resolve this clinical impasse and inform treatment algorithms.

.
Citation
Ortopedia Traumatologia Rehabilitacja, 28(1), 15-22, 2026
Subjects

Kellgren-Lawrence gra...

Key words: knee osteo...

mesenchymal stem cell...

PRISMA 2020

quality of life

regenerative medicine...

total knee arthroplas...

Metrics
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback